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Abstract
Background: Insomnia is perhaps the most common sleep disorder in the general population, and is characterised
by a range of complaints around difficulties in initiating and maintaining sleep, together with impaired waking
function. There is little quantitative information on treatment pathways, costs and outcomes. The aims of this New
Zealand study were to determine from which healthcare practitioners patients with insomnia sought treatment,
treatment pathways followed, the net costs of treatment and the quality of life improvements obtained.
Methods: The study was retrospective and prevalence based, and was both cost effectiveness (CEA) and a cost
utility (CUA) analysis. Micro costing techniques were used and a societal analytic perspective was adopted. A
deterministic decision tree model was used to estimate base case values, and a stochastic version, with Monte
Carlo simulation, was used to perform sensitivity analysis. A probability and cost were attached to each event
which enabled the costs for the treatment pathways and average treatment cost to be calculated. The inputs to
the model were prevalence, event probabilities, resource utilisations, and unit costs. Direct costs and QALYs gained
were evaluated.
Results: The total net benefit of treating a person with insomnia was $482 (the total base case cost of $145 less
health costs avoided of $628). When these results were applied to the total at-risk population in New Zealand
additional treatment costs incurred were $6.6 million, costs avoided $28.4 million and net benefits were $21.8
million. The incremental net benefit when insomnia was “successfully” treated was $3,072 per QALY gained.
Conclusions: The study has brought to light a number of problems relating to the treatment of insomnia in New
Zealand. There is both inadequate access to publicly funded treatment and insufficient publicly available
information from which a consumer is able to make an informed decision on the treatment and provider options.
This study suggests that successful treatment of insomnia leads to direct cost savings and improved quality of life.
Background
Insomnia is a disorder defined by difficulty initiating or
maintaining sleep, or non-restorative sleep, along with
impaired daytime function. These problems arise despite
adequate time and opportunity for sleep [1,2]. Insomnia
may occur as primary insomnia or insomnia comorbid to
other medical or psychological conditions, substance
abuse, or other sleep disorders. The outcomes of untreated
insomnia are not well understood but it is known that
insomnia is associated with a number of adverse health
outcomes such as poor physical health, poor mental health
including symptoms of anxiety and depression, and
decreased quality of life [3,4]. There is currently no sys-
tematic national approach to insomnia diagnosis or treat-
ment in New Zealand, and no requirement for treatment
providers to have formal training or registration.
Aims
The study aims are encapsulated in the following
questions.
Policy question: in New Zealand, from which health-
care practitioners do patients seek treatment for insom-
nia, to whom are they referred, and what is the net cost
and provider-assessed outcome of this treatment?
Research question: What are the effects of successful
insomnia treatment on quality of life and health resource
utilisation?
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The following search engines were used to identify the
literature that investigated the economic dimensions of
insomnia; MEDLINE, Cochrane Library, AHRQ (Agency
for Healthcare Research and Quality) Google Scholar
and relevant New Zealand and Australian sites. Key
words searched on included the following used alone
and in various combinations; insomnia, cost, economic,
analysis, Australia, New Zealand, UK, USA, America.
We reviewed and summarised the main findings of rele-
vant papers published from 1996 onwards. The literature
was then grouped into four categories; those papers that
considered the prevalence of insomnia, the burden or cost
of illness, resource utilisations, and quality of life. There
was a wide variation in the data within each of these cate-
gories because the studies differed in their definition of
insomnia. The literature reviewed aided in the selection of
the base case values and ranges for the incremental
resource utilisations and outcomes.
From the international literature, insomnia prevalence
was estimated at 5-35% [5]. This wide range in prevalence
stems in most part from the many definitions of insomnia
used in previous research. Thirty percent of individuals
report symptoms of insomnia and 15-20% report insomnia
symptoms with daytime impairment, whereas 5-10% meet
criteria for a diagnosis of insomnia according to standar-
dised diagnostic criteria [1,2]. New Zealand prevalence
data align well with the international literature. Based on a
national survey of insomnia symptoms [6,7], 25% of New
Zealanders report having a sleep problem lasting longer
than six months. From these data, we have estimated that
13% of New Zealanders are affected by at least one symp-
tom of insomnia often/always, together with excessive day-
time sleepiness [8]. Considerable disparity in estimated
insomnia prevalence was observed between Māori (19.1%)
and non-Māori (8.9%).
The burden of illness cost estimates for insomnia ran-
ged from 0.2% to 0.5% of Gross Domestic Product
(GDP), with a mean and median of 0.3% [9-13]. The
Australian study [9] calculated that all sleep disorders
represented 1.3% of GDP.
There were greater numbers of more recent studies
that compared resource utilisations (direct and indirect)
of individuals with insomnia with those of good sleepers.
The differences in direct health costs between these two
groups ranged from 5% to 200% (mean 57%, median
24%) [14-20]. Two high outliers [15,16] were eliminated
resulting in a plausible range of 5-25%, with a mean of
18% and median of 21%. Insomniacs’ absences from work
(indirect costs) were higher by 15% to 142% (mean 86%,
median 68%) compared with good sleepers [14,16,18,21].
The quality of life (QoL) studies in the international
literature varied in the terminology they used to
describe insomnia, some using descriptors that were not
in accord with accepted diagnostic criteria. However, as
most of the quality of life studies used the SF-36 on a
scale of 0 to 100 points, the reduction in quality of life
for the “physical functioning” and “mental health”
domains/dimensions, or QoL scores, for insomniacs
compared with good sleepers was able to be assessed
[22-24]. Approximately 20% of all motor vehicle acci-
dents are associated with driver sleepiness (independent
of alcohol) [25]. Those reporting disrupted sleep were
almost twice as likely (relative risk 1.89) to die in a
work related accident [26] and 69% more likely to have
a serious accident [27].
There were no reported studies of the proportion of
insomniacs treated in New Zealand but findings from the
United States suggest the majority of people (85%) who
suffer from insomnia do not seek treatment [28]. A United
Kingdom study [29] (sample size 85) investigated where
insomniacs sought treatment and found that the providers
most likely to have been consulted were; pharmacist
(16.5%), general practitioner (41.2%), psychiatrist (3.5%),
psychologist (7.1%), nurse (3.5%), counsellor (10.6%), herb-
alist (8.2%), acupuncturist (8.2%), and hypnotist (4.7%).
Methods
This economic evaluation was a combination of cost
effectiveness (CEA) and cost utility (CUA) analyses. The
study used micro costing techniques, and was retrospec-
tive and prevalence-based. A societal analytic perspective
was adopted and all costs were measured incrementally
compared with the counterfactual (no intervention). As
a time horizon of one year was used, discounting of
costs and effects was not undertaken.
This study was informed by both the international litera-
ture and a series of key informant interviews [30] to can-
vas the range of treatment options offered in New Zealand
and to estimate the proportion of people with insomnia
who seek treatment. In order to ensure the interview data
were representative of the range of insomnia diagnostic
and treatment options available in New Zealand, infor-
mants were categorised as specialist physician (appropri-
ately qualified physician working in specialty medical
practice other than general practice), general practitioner
(GP), psychologist, pharmacist, health practitioner (a
medically-trained GP or other qualified health practitioner
who has taken an interest, or undergone some training, in
sleep) and alternative health practitioner (a treatment pro-
vider with any level of training in alternative medicine,
practising insomnia treatment). An equal number of infor-
mants from each category were sought for interview.
Information was sought on the profile of patients (who
had they previously consulted, number of new/referred
patients, patient demographics), clinical practice (diagno-
sis, knowledge, treatments), patient outcomes (consulta-
tions, referrals, treatment effectiveness), and fees charged.
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and could not be independently verified.
The interviews were not sufficient to accurately
describe insomnia patient treatment pathways and there
is a paucity of data in the international literature. For
the purposes of the model, findings from Stinson et al.
[29] were used to estimate the percentage of patients
approaching each provider type in the first instance. To
correspond with the study of Stinson et al. (2006),
patients approaching a nurse or counsellor were
grouped in the category ‘health practitioner’,a n d
patients approaching a herbalist, acupuncturist and hyp-
notist were grouped in the category ‘alternative health
practitioner’.
A decision tree was developed to reflect treatment
options for insomnia and modified when the findings of
the key informant interviews were completed. The
deterministic model developed was used to estimate
base case values, and a stochastic version (with Monte
Carlo simulation) was used to perform multivariate sen-
sitivity analysis. Key methodological steps are shown in
Figure 1. The decision tree represents a simplification of
reality in that not every possible branch that a patient
may follow has been included and the model was lim-
ited to one level of on-referral. The inputs to the model
were prevalence, event probabilities, resource utilisations
and unit costs. A schematic description of the
calculations performed by the decision tree model is
represented in Figure 2.
An individual with suspected insomnia may choose
between two pathways; that is, they do not seek treat-
ment or they seek treatment from a healthcare practi-
tioner/provider. If they do not seek treatment, different
outcomes may occur resulting in increased use of health
resources, reduced productivity and reduced quality of
life. The person with insomnia may have any or all of
these outcomes in any combination. Based on the
national prevalence data [6-8] the population at risk
used for the model was 20-59 years (2.317 million) [31]
and the prevalence of insomnia 13%. Event probabilities,
costs and the referral pathways were determined from
the literature [29] and interviews. While the interna-
tional literature suggests that insomnia is associated
with a range of other medical conditions, the cost of co-
morbidities has not been included as the causal relation-
ships between insomnia and comorbid conditions are
not well understood.
Two of the insomnia practitioners who had partici-
pated in the interviews completed a EuroQol 5D (EQ-
5D) questionnaire relating to their insomnia patients
both before treatment and after practitioner-rated suc-
cessful treatment. The EQ-5D was scored using the New
Zealand-specific tariff (utility weights, tariff 2) [32]. The
SF-36 scores for the two domains (“physical functioning”
and “mental health”) were converted from 0 - 100 to the
scale 0 - 1 and then averaged. Scores from the literature
taken from groups with the closest approximation to a
standard clinical definition of insomnia (for example,
‘severe” or “level II” insomnia) [19,22,23] and the EQ-5D
clinician scores were combined into one dataset (range
0.078 to 0.373, mean 0.157). The dataset provided the
base case (mean) and the high value, and 0 was assumed
for the low value.
Direct medical provider costs and the indirect medical
cost of transport to seek treatment were quantified but
indirect costs (loss of productivity including travel time)
and the non-health costs of accidents were not evalu-
ated. It was assumed that the cost of any behavioural or
psychological therapy, if given by any of the healthcare
practitioners, was included in the fee for the initial visit.
Unit resource cost estimates are described in table 1.
The interviews provided data on medicines prescribed
and this was supplemented with information from the
Pharmaceutical Management Agency of New Zealand
( P H A R M A C )t oc o s tt h em o s tprescribed medicine for
insomnia, Zopiclone [33]. The interviews also supplied
information on non-prescription products (over-the-
counter preparations sold by Pharmacists) and the unit
costs were taken from the website of Pharmacy Direct
[34]. Blackmores Valerian Forte 2000 mg was used for
the base case. Private motor vehicle costs incurred
Decision tree model 
Ļ 
Interviews 
Ļ 
Tree pathways modified 
Ļ
Data inputs
Ļ
Base case – deterministic tree model 
Ļ 
Sensitivity analysis – stochastic model
Figure 1 Methodological steps.
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multiplying the average cost per kilometre of $0.56 [35]
by the average distance travelled for a round trip
(29.83 km) to a GP or hospital clinic [36].
The event probabilities are summarised in Figure 3. At
each node choices are made, events take place and
resource utilisations are changed. If, for example, a person
who has insomnia consults their Pharmacist they may pur-
chase an over-the-counter (OTC) medication and incur
transport costs. (See table 2) The average increase in
health resource utilisations for those with insomnia versus
non-insomniacs were derived from the literature (table 3).
Figure 2 Decision tree descriptions of calculations. (1) Decision tree cost = the sum of all pathway costs (2) Cost of an event = the sum of
(the unit costs of all resources utilised by the event multiplied by the volume of resources utilised) (3) Probability of a pathway = (pE1 ×p E 2 ...
xpEI ... xpEn) where EI = eventI, and n = the total number of events in the pathway (4) Cost of a pathway = the sum of the cost of all events in
pathway (5) A decision tree enables a method of modelling, in chronological order, all possible events (6) Resources = consultations, medicines,
and transport, E = event, p = probability (7) ● = Chance node which has a branch for each possible outcome or event. Each event ha s an
associated probability and value. (8) ◀= End node which does not have any succeeding braches. Each end node returns a probability and a
value for the associated pathway. Upper value = probability of reaching the end point of the pathway. Lower value = cost incurred in reaching
the end point of the pathway.
Table 1 Unit resource cost estimates in 2009 NZ dollars
Resource Base case $ Year of data Notes
Direct medical
General Practitioner 48.89 2009 (1)
Specialist Physician initial 222.22 2009 (1)
Specialist Physician follow up 99.56 2009 (1)
Psychologist 88.89 2009 (1)
Health Practitioner 120.00 2009 (1)
Alternative Health Practitioner 75.56 2008 (2)
Prescription medicine 6.42 2009 (3)
Non prescription medicine 16.00 2009 (4)
Increase in cost per capita for those with insomnia versus non-insomniacs 627.52 2008 (5)
Direct non-medical
Transport for treatment (round trip) 16.71 2009 (6)
Notes:
(1) Registered health care providers [40]. General Practitioner, medical practitioner band 1. Specialist Physician, medical practitioner band 2; high case
(interviews). The medical fees do not include any government patient subsidy as this varies between providers and patients.
(2) Alternative Health Practitioner from Interviews.
(3) Prescription medicine, Zopiclone, base case 7.5 mg @ 30 days plus dispensing fee, low case = base case × 0.5 plus dispensing fee, high case = two
prescriptions plus 2 dispensing fees (Interviews) and dispensing fee [39], prices [33].
(4) Non prescription medicine (Interviews) and [34], low case = base case less 25%, high case = base case × 2.
(5) See Table 3.
(6) Transport for treatment: Cost per km × km travelled for round trip = $0.63/9 × 8 × 29.83 km = $16.71. [Cost per km $0.63/9 × 8: 1500-2000 cc petrol: [35].
Time to hospital (17.9 minutes): [36]. Distance for round trip (km): 17.9 minutes @ 50 km/hour × 2 = 29.83 km.]
Ranges: if not specifically stated ranges = base case plus or minus 25%.
All costs have had GST of 12.5% deducted and calculations are based on unrounded data.
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used to investigate uncertainty in the model inputs (unit
costs, resource utilisations, QALYs, and prevalence). A
stochastic version of the insomnia costing model, using
Monte Carlo sampling from triangular distributions, was
used for multivariate sensitivity analysis [37]. Triangular
distributions were used because there was insufficient
information from which to define specific distributions
(for example, normal or Pareto distributions). Unless
otherwise stated, all estimates subject to uncertainty were
0.050 0.008
$72.02 $104.72
0.165 1 Pharmacist
$32.71 $36.31
0.950 0.157
$0.00 $32.71
0.350 0.144
$0.00 $65.60
0.412 2 GP
$65.60 $98.26
0.875 0.234
$0.00 $72.02
0.650 Treat
$6.42 $115.85
0.400 0.013
$422.38 $494.40
0.125 Refer
$0.00 $422.66
0.200 0.007
$361.61 $433.63
0.400 0.013
$273.41 $345.43
Mean cost per patient treated (weighted over all treatment modalities in the decision outcome tree)
$145.16
0.050 0.007
$0.00 $136.71
0.141 (3) HP
$136.71 $212.91
0.775 0.104
$0.00 $139.92
0.950 Treat
$3.21 $216.92
0.333 0.010
$422.38 $562.30
0.225 Refer
$0.00 $482.14
0.333 0.010
$361.61 $501.53
0.167 0.005
$72.02 $211.93
0.167 0.005
$413.33 $553.25
0.025 0.002
$0.00 $105.60
0 071 4 Psychologist
1.2 Success
1.1 Refer GP
2.2 Treat
2.2.1 Success
2.1 No further action
3.2 Treat
3.2.1 Success
3.1 No further action
4.1 No further action
1 Pharmacist
2 GP
3 HP
4 Psychologist
Insomnia treatment
2.2.2.1 Psychologist
2.2.2.2 Specialist Physician
2.2.2.3 Health Practitioner
2.2.2 Refer
3.2.2.1 Psychologist
3.2.2 2 .Specialist Physician
3.2.2.3 GP
3.2.2.4 Health Practitioner
3.2.2 Refer
0.071 4 Psychologist
$105.60 $134.27
0.838 0.058
$0.00 $105.60
0.975 Treat
$0.00 $135.01
0.133 0.001
$422.38 $527.98
0.162 Refer
$0.00 $287.15
0.267 0.003
$361.61 $467.21
0.400 0.004
$72.02 $177.61
0.200 0.002
$0.00 $105.60
0.000 0.000
$0.00 $92.26
0.211 5 Alt HP
$92.26 $280.26
0.963 0.203
$0.00 $276.79
1.000 Treat
$184.52 $280.26
0.375 0.003
$184.52 $461.31
0.037 Refer
$0.00 $370.58
0.375 0.003
$65.60 $342.38
0.250 0.002
$0.00 $276.79
1.2 Success
1.1 Refer GP
2.2 Treat
2.2.1 Success
2.1 No further action
3.2 Treat
3.2.1 Success
3.1 No further action
4.1 No further action
5.1 No further action
5.2.1 Success
5.2 Treat
5.2.2.1 Other Alt HP
5.2.2.2 GP
5.2.2.3 No further action
5.3.2 Refer/ no further action
4.2.2.1 Other Psychologist
4.2.2.2 Specialist Physician
4.2.2.3 GP
4.2.2.4 No further action
1 Pharmacist
2 GP
3 HP
4 Psychologist
5 Alt HP
Insomnia treatment
4.2.1 Success
4.2.2 Refer/ no further action
4.2 Treat
2.2.2.1 Psychologist
2.2.2.2 Specialist Physician
2.2.2.3 Health Practitioner
2.2.2 Refer
3.2.2.1 Psychologist
3.2.2 2 .Specialist Physician
3.2.2.3 GP
3.2.2.4 Health Practitioner
3.2.2 Refer
Figure 3 Insomnia treatment model.
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high and low limits. Ten thousand iterations of
the model were run. The Monte Carlo simulations used
Palisade’s Decision Tools Suite software.
All unit costs were valued in 2009 NZ dollars (or the lat-
est available data) and were exclusive of GST (goods and
services tax, a transfer payment from one sector of society
to another). New Zealand dollar conversions; mid rates
end Dec 2009 NZD1 = AUD0.7929, €0.4901, USD0.7162
[38].
Results
The interviews revealed little awareness of international
best practice standards for insomnia treatment. Alternative
Table 2 Resource utilisations by event
Events (a) (b) (c) (d) (e) (f) (g) (h) (i)
Do not seek treatment
Seek treatment
1 Pharmacist 1.0 1.0
1.1 Refer General Practitioner 1.0 1.0 1.0
1.2 Success
2 General Practitioner 1.0 1.0
2.1 No further action
2.2 Treat 1.0
2.2.1 Success
2.2.2 Refer
2.2.2.1 Psychologist 4.0 4.0
2.2.2.2 Specialist Physician 1.0 1.0 1.0 2.0
2.2.2.3 Health Practitioner 2.0 2.0
3 Health Practitioner 1.0 1.0
3.1 No further action
3.2 Treat 0.5
3.2.1 Success
3.2.2 Refer
3.2.2.1 Psychologist 4.0 4.0
3.2.2.2 Specialist Physician 1.0 1.0 1.0 2.0
3.2.2.3 General Practitioner 1.0 1.0 1.0
3.2.2.4 Other Health Practitioner 3.0 0.5 3.0
4 Psychologist 1.0 1.0
4.1 No further action
4.2 Treat
4.2.1 Success
4.2.2 Refer/no further action
4.2.2.1 Other Psychologist 4.0 4.0
4.2.2.2 Specialist Physician 1.0 1.0 1.0 2.0
4.2.2.3 General Practitioner 1.0 1.0 1.0
4.2.2.4 No further action
5 Alternative Health Practitioner 1.0 1.0
5.1 No further action
5.2 Treat 2.0 2.0
5.2.2 Success
5.2.3 Refer/no further action
5.2.3.1 Other Alternative Health Practitioner 2.0 2.0
5.2.3.2 General Practitioner 1.0 1.0
5.2.3.3 No further action
Notes:
Events: (a) General Practitioner consultation, (b) Specialist Physician Initial consultation, (c) Specialist Physician follow-up consultation, (d) Psychologist
consultation, (e) Health Practitioner consultation, (f) Alternative Health Practitioner consultation, (g) Prescription medicine, (h) Non prescription medicine, (i)
Transport for treatment (round trip)
Base case values were derived from the current study. Monte Carlo simulation runs used base case, and ranges base case plus or minus 25%.
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pared with specialist physicians, health practitioners) and
had poorer knowledge of the types of insomnia and sleep
terminology, were less likely to use any structured diag-
nostic tools and offered the most limited range of treat-
ment options. The effectiveness of treatment provided was
formally assessed by 57%. The interviewees suggested that
patients had frequently consulted multiple practitioners. It
was considered that there was an unmet need for insom-
nia treatment and a lack of accurate information on treat-
ment options and providers.
The decision tree (Figure 3) is the final version devel-
oped and used for modelling treatment pathways and
costs. The pathways and events depicted are the domi-
nant and most relevant for which local data existed.
Treatment cost over all treatments (the tree cost) aver-
aged $145 per patient. The mean treatment cost for each
branch or mode of treatment designated by the health
practitioner first consulted was as follows; pharmacist
$36, GP $98, psychologist $134, health practitioner $213,
and alternative health practitioner $280. The total direct
costs for each treatment outcome or pathway that ended
in a termination node ran from a low of $33 (cost of an
OTC product and travel, pharmacist pathway) to a high
of $562 (psychologist accessed through a health practi-
tioner pathway). The direct costs of treatment by a spe-
cialist physician depended upon the referral pathway
taken and ranged from $434 (accessed through a GP) to
$502 (when accessed through a health practitioner).
The total net benefit of treating a person with insom-
nia was $482 (the total base case cost of $145 less costs
avoided of $628). When these results were applied to
the total at-risk population in New Zealand treatment
costs incurred were $6.6 million, costs avoided $28.4
million and net benefits were $21.8 million. The incre-
mental net direct benefit per QALY gained when insom-
nia was successfully treated was $3,072 (table 4). When
multivariate sensitivity analysis was undertaken on the
Table 3 Health care cost of those with insomnia versus non-insomniacs
Item Base Case Year of data Notes
Per capita health care resource cost ($) of all ages New Zealand population (TP$) 3,568 2008 (1)
Personal medical services ($M) 15,313 2008 (2)
Population all ages (M) 4.292 2008 (3)
Proportion of New Zealand population suffering from insomnia (Ip) 0.13 (4)
% Increase in cost per capita of those with insomnia versus non-insomniacs 18.0% (5)
Ratio of health resource cost of those with insomnia to non-insomniacs (R) 1.18 (5)
Mean health care resource cost ($) of non-insomniacs (Y) 3,486 (6)
Mean health care resource cost ($) of those with insomnia (X) 4,114 (6)
Increase in cost per capita those with insomnia versus non-insomniacs 628 (6)
Notes:
Data sources
(1) = (2) ÷ (3)
(2) Personal medical services: excludes expenditure on prevention and public health, administration and insurance premiums [41].
(3) Population: Total resident population[31]
(4) [8]
(5) [14,17-20]
(6) Derivation of “Y” and “X” from “Ip”“ R” and TP$
Unknown
X = Mean health care resource cost ($) of those with insomnia
Y = Mean health care resource cost ($) of non-insomniacs
Known (Statements S1, S2, S3)
(S1): Ip = Proportion of New Zealand population suffering from insomnia, [base case 0.13]
(S2): R = Ratio of health resource cost of those with insomnia to others, [base case 1.18]
(S3): TP$ = Mean health care resource cost of total all ages New Zealand population, [base case $3,568]
Solution
(S1) and (S3) may be used to derive equation (E1): TP$ = Ip × X + [(1 - Ip) × Y] (S2) may be written as equation (E2): × = R × Y
Substitute (E2) into (E1)
TP$ = [Ip × R × Y] + [(1 - Ip) × Y]
TP$ = Y × [(Ip × R) +1 - Ip)]
Solve for Y
Y = TP$/[(Ip × R) + 1 - Ip]
Using base case values as an example
Y = $3,568/[(0.13 × 1.18)+1-0.13] = $3,486
X = ($3,486 × 1.18) = $4,114
All calculations are based on unrounded data.
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the Monte Carlo 10,000 simulations the net benefit of
treatment per person fell between $41 and $679, and for
New Zealand as a whole between $2 million to $33 mil-
lion. The net benefit per QALY gained ranged between
$240 and $8,102.
Discussion
We now have a greater understanding of the treatment
of insomnia in New Zealand in terms of the types of
diagnostic and treatment options being used. Both the
information on the impact on health resource utilisation
and improved quality of life (if insomnia is successfully
treated) should assist in identifying cost-effective treat-
ments and policies. The model developed may be used
to investigate population subgroups and evaluate differ-
ent treatment options.
The cost of each treatment path varied, depending not
only on the fees charged and the number of consultations
per course of treatment but also upon the number of
encounters with different healthcare practitioners/treat-
ment providers (referrals). The study assumed a successful
treatment outcome (no further additional impact on
health resource utilisations) at each termination node. As
individuals with insomnia are more likely to consult their
Pharmacist or GP in the first instance, it is important that
both these practitioners have clear guidelines and proto-
cols to identify potential insomnia and where appropriate,
on-refer a patient to a trained treatment provider.
There are no publicly funded treatment options for
insomnia in New Zealand. Market failure caused by
insufficient patient information is indicated in that the
interviews found that it was not uncommon for patients
with insomnia to have independently consulted several
practitioners. It was considered that those with insomnia
lacked sufficient accurate and unbiased information from
which they were able to make an informed decision.
Sensitivity analysis demonstrated that the results were
robust with respect to changes in key assumptions and
determinants of cost and effects (over 90% of all itera-
tions were both more effective and less costly). By way
of comparison, the cumulative average cost-effectiveness
threshold of PHARMAC funding decisions for new
medicines made between 1999 and 2005 was $6,865
[39].
The study is the first in New Zealand to attempt to
ascertain the treatment pathways that a person with
insomnia may follow. It also sought to understand the
treatment provided (based on interviews of healthcare
practitioners) and to quantify the costs of insomnia and
its impact on quality of life.
Limitations
Individuals with insomnia access health care services more
often than others, and insomnia is associated with a range
of other medical conditions. However, the causal relation-
ship between insomnia and these comorbid conditions is
not well understood. Thus, the costing model in this study
did not specifically account for conditions that may be
caused by insomnia but instead evaluated the impact on
total health resource utilisation, using information from
international studies. Costs of non-prescription medicines
from health food stores and supermarkets or from web-
based vendors were not considered.
Individuals with insomnia may be at increased risk for
decreased performance and accident or injury. This is best
described in relation to motor vehicle accidents; those
with insomnia have a higher motor vehicle accident rate
than controls [27]. However, the relative risk of decreased
performance in those with insomnia is not well under-
stood. This study has taken a conservative approach. For
example, a person with insomnia has increased non-health
costs of having an accident, injuring others and/or dama-
ging property but this was not considered. In addition, the
analyses did not quantify externalities that impact on
others in the community such as the effect on productivity
and quality of life of having an insomniac within a family
setting. Thus, we did not calculate the burden of illness as
a percentage of GDP.
As healthcare practitioners were interviewed (and not
patients), it is their judgements on pathways, and patient
outcomes that have been used to define the model.
Thus, the true success of treatment by these providers
remains unknown. Costs incurred by those 60 years and
older were not included as the at risk population was
limited by the available insomnia prevalence estimates
for New Zealanders aged 20-59 years.
Table 4 Economic evaluation of insomnia treatment
versus no treatment
Per person
treated
NZ total
million
At risk population (1) 2.317
Prevalence of insomnia (2) 13%
Proportion seeking treatment (2) 15.0%
Number seeking treatment (M) (3) 0.045
Costs incurred ($) 145 6.6
Costs avoided ($) 628 28.4
Net benefit ($) 482 21.8
QALYs gained (#) 0.157 0.007
Net benefit per QALY gained
($)
3,072 21.8
Notes:
(1) December 2008 [31]
(2) [8]
Ranges (1) and (2) The high values are the base case plus 25% and the low
values the base case minus 25%.
(3) = (1) × (2) × (3)
Calculations are based on unrounded data.
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A larger nationwide survey of those offering insomnia
treatments would provide a greater understanding of diag-
nostic, treatment and referral practices in New Zealand,
and would give a more comprehensive sample on which
to base QALY estimates. A large survey of individuals in
New Zealand who identify as having insomnia would pro-
vide a means to more accurately identify the difference in
healthcare resource utilisations and productivity between
those people with untreated insomnia, treated insomnia
and those without insomnia and to determine patients’
evaluation of the effectiveness of the various treatments
and treatment pathways followed. The existing model,
augmented by additional national survey data, could be
modified and used to evaluate the cost of alternative fund-
ing policies and treatment options.
Conclusions
The interviews highlighted the unsystematic approach to
insomnia treatment in New Zealand. It is concerning
that there is insufficient publicly available information
from which a consumer is able to make an informed
decision on treatment provider options and provider
competence. A standardised approach to insomnia treat-
ment requires a multi-disciplinary team of treatment
providers who have sufficient knowledge to diagnose
insomnia, implement treatment and measure treatment
efficacy. This would reduce the direct and indirect costs
of insomnia and improve quality of life.
A number of study limitations resulted in a conserva-
tive estimate of the costs of insomnia treatment in New
Zealand. Despite this conservative approach, this study
confirms that successful treatment of insomnia is highly
cost effective.
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